Different human MM cell lines [SKO-007(J3), ARP-1 and RPMI-8226] were treated with JQ1, a small molecule bromodomain inhibitor displaying potent binding affinity to BET family proteins48, and with ARV-825, a PROTAC consisting of a BRD4 binding moiety (triazolo-diazepine acetamide class in the BETi OTX015) chemically linked to the IMiD Pomalidomide, a structure able to recruit BRD4 to CRBN and to induce its rapid degradation via the proteasome25,26. Here, CRBN is linked to Miyoshi myopathy.